福森藥業(01652.HK):江西康德與康川濟設合營開發兩種治療糖尿病外周神經痛及慢性心臟衰竭藥品
格隆匯2月1日丨福森藥業(01652.HK)發佈公吿,於2021年1月22日,公司間接擁有約35.8%權益的公司合營企業江西永豐康德醫藥有限公司與獨立第三方南京康川濟醫藥科技有限公司訂立戰略合作協議,據此,江西康德與康川濟同意成立合營公司,以共同開發兩種治療糖尿病外周神經痛及慢性心臟衰竭的藥品。
根據戰略合作協議,合營企業的註冊資本應為人民幣6000萬元,其中人民幣3600萬元將由江西康德以現金出資,而康川濟將以其於該等藥品知識產權的全部權益作為無形資產出資(約為人民幣2400萬元)。江西康德及康川濟將分別擁有合營企業的60%及40%股權。合營企業將成為江西康德非全資附屬公司。
南京康川濟醫藥科技有限公司為一間於中國成立的有限公司,主要於中國從事藥品研發。
公司表示,公司一直尋求機會豐富現有產品組合,以把握未來機遇及透過(其中包括)收購或與其他實體合作提升其股東回報。董事會相信,成立合營企業可將江西康德在新藥品商業化方面的經驗與康川濟在藥品研發方面的先進技術相結合,為集團的業務發展提供業務協同效應。尤其是,董事認為合營企業可加快推進該等藥品註冊並推出,並將於2021年就此應用臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.